IPCAVDIntegrated Preclinical/Clinical AIDS Vaccine Development (National Institutes of Health program)
References in periodicals archive ?
Harriet Robinson, Chief Scientific Advisor for GeoVax, guided development of the IPCAVD proposal and will lead a major part of its related studies.
R&D expenses include direct costs funded by the IPCAVD grant, as well as vaccine manufacturing costs and expenses related to the Phase 1/2 clinical trial, being sponsored by GeoVax, of the Company's therapeutic HIV vaccine.
9 million related to the IPCAVD grant and a one-time award of $244,000 pursuant to the Qualifying Therapeutic Discovery Project (QTDP) program enacted as part of the Patient Protection and Affordable Care Act of 2010.